Valuation: Assembly Biosciences, Inc.

Market Cap 543M 475M 438M 405M 768M 51.79B 781M 5.23B 2.06B 25.51B 2.04B 1.99B 87.71B P/E 2026 *
-25.3x
P/E 2027 * -9.56x
Enterprise Value 543M 475M 438M 405M 768M 51.79B 781M 5.23B 2.06B 25.51B 2.04B 1.99B 87.71B EV / Sales 2026 *
11.9x
EV / Sales 2027 * 16.8x
Free-Float
71.58%
Yield 2026 *
-
Yield 2027 * -
1 day-1.69%
1 week-1.23%
Current month-0.29%
1 month+19.34%
3 months-3.59%
6 months-11.41%
Current year-19.44%
1 week 26.45
Extreme 26.45
29.94
1 month 22.58
Extreme 22.58
29.94
Current year 21.8
Extreme 21.795
34.68
1 year 16.9
Extreme 16.9
39.7
3 years 7.69
Extreme 7.692
39.7
5 years 7.69
Extreme 7.692
47.28
10 years 7.69
Extreme 7.692
808.32
Manager TitleAgeSince
Chief Executive Officer 50 01/01/2023
Director of Finance/CFO - 05/06/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 61 14/12/2017
Director/Board Member 54 20/10/2020
Chairman 70 04/06/2026
Date Insider Type Main position Quantity % Market Cap.
06-17Sell

Chief Financial Officer

-29 0.0002%
06-04Free

Director

8,000 0.0514%
06-04Free

Director

8,000 0.0514%
Change 5-day change 1-year change 3-year change Capi.($)
-1.69%-1.23%+46.13%+109.48% 543M
-0.27%+0.83%+3.65%+10.17% 50.73B
-2.22%-1.25%+391.53%+593.69% 39.73B
-0.54%+0.39%+27.67%-5.10% 34.69B
-1.36%+0.35%+19.34%+55.53% 33.21B
+1.21%-4.58%+3.00%+31.73% 26.76B
-1.81%-1.48% - - 16.8B
+0.51%-3.47%+66.38%+122.57% 15.37B
+0.44%+0.82%+15.13%+16.91% 13.78B
-0.62%-3.09%+11.43%-31.02% 12.85B
Average -0.64%-0.87%+64.92%+100.44% 24.45B
Weighted average by Cap. -0.65%-0.23%+82.69%+124.74%

Financials

2026 *2027 *
Net sales 45.47M 39.77M 36.69M 33.88M 64.29M 4.34B 65.37M 438M 172M 2.14B 171M 167M 7.34B 32.25M 28.21M 26.02M 24.03M 45.6M 3.08B 46.37M 311M 122M 1.52B 121M 118M 5.21B
Net income -20.46M -17.9M -16.51M -15.25M -28.93M -1.95B -29.42M -197M -77.46M -961M -76.83M -75.16M -3.31B -56.38M -49.31M -45.49M -42.01M -79.71M -5.38B -81.05M -543M -213M -2.65B -212M -207M -9.11B
Net Debt - -
Logo Assembly Biosciences, Inc.
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. It is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).
Employees
73
Date Price Change Volume
10/07/26 $27.40 -1.69% 169,991
09/07/26 $27.87 -2.99% 179,144
08/07/26 $28.73 -0.81% 135,958
07/07/26 $28.97 +0.24% 177,789
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
27.40USD
Average target price
50.00USD
Spread / Average Target
+82.48%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ASMB Stock